Kunio Yamada

Profile
Tenure
Jun 1999 – Jun 2009
Years in office
10.0 years
Name in Japanese
山田邦雄
Title at appointment
Representative Director, President
Performance in office
Rohto Pharmaceutical
Performance in office
FY1999FY2009Change
Revenue¥41.6billion¥110.6billion+166%
Net margin4.9%5.5%+0.6pt
Yasukuni YamadaKunio YamadaYoshino
Revenue¥21.0 billionRevenue¥67.3 billionRevenue¥143.8 billionNet margin4.2%Net margin5.6%Net margin6.2%1994/31999/32004/32009/32014/3
Revenue¥21.0 billionRevenue¥67.3 billionRevenue¥143.8 billionNet margin4.2%Net margin5.6%Net margin6.2%1994/31999/32004/32009/32014/3
Tenure

Tenure

Background

He joined Rohto Pharmaceutical in April 1980. He became a Director in June 1991, 11 years after joining, Senior Managing Director in June 1992, 12 years after, and Executive Vice President in June 1996, 16 years after. In the fiscal year ended March 2006, during his presidency, the major shareholders included Yamada Kosan at 3.55%, Yamasho Kosan at 3.06%, Nomura Trust and Banking (Shigeko Yamada trust account) at 2.72%, Kiyoko Yamada at 2.59% and Yasusada Yamada at 1.88%. Five of the top ten were individuals named Yamada and unlisted companies, and he appears to have had the founding family's capital behind him.

Education: University of Tokyo, Faculty of Science, Physics (1979)

Selection

He became Executive Vice President in June 1996 and President three years later, in June 1999. The promotion came 19 years after he joined. The year before, in July 1998, he had also become Chairman of Mentholatum, and he appears to have been appointed from a position running an overseas subsidiary. Results around the time he took office can be traced in the annual securities reports only from the fiscal year ended March 2003, so what was happening when he took office cannot be followed in figures.

Initiatives

Consolidated net sales in the fiscal year ended March 2000, his first year, were ¥55.7 billion. In FY ended March 2003 the company posted a net loss of ¥1.30 billion, but returned to net income of ¥3.74 billion in FY ended March 2004. Sales grew steadily from then on, reaching ¥108.1 billion with operating income of ¥13.0 billion in FY ended March 2008, and ¥110.6 billion with net income of ¥6.1 billion in FY ended March 2009, the year he stepped down, nearly double his first year.

Career

Career

Rohto Pharmaceutical

Date Position
Apr 1980 Joined
Jun 1991 Director
Jun 1992 Senior Managing Director
Jun 1996 Executive Vice President
Jun 1999 Representative Director, President
Jun 2009 Representative Director, Chairman and CEO
Jun 2009 Stepped down as President
Jun 2019 Representative Director, Chairman

Mensoretamu

Date Position
Jul 1998 Chairman
References 1

References (Japanese primary sources)

  • ロート製薬 有価証券報告書【役員の状況】